EyePoint Pharmaceuticals (EYPT) Stock Forecast, Price Target & Predictions
EYPT Stock Forecast
EyePoint Pharmaceuticals stock forecast is as follows: an average price target of $22.00 (represents a 208.99% upside from EYPT’s last price of $7.12) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
EYPT Price Target
The average price target for EyePoint Pharmaceuticals (EYPT) is $22.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $22.00 to $22.00. This represents a potential 208.99% upside from EYPT's last price of $7.12.
EYPT Analyst Ratings
According to 6 Wall Street analysts, EyePoint Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for EYPT stock is 0 'Strong Buy' (0.00%), 6 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
EyePoint Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 11, 2024 | Yi Chen | H.C. Wainwright | $22.00 | $11.59 | 89.90% | 208.99% |
| May 13, 2024 | Yi Chen | H.C. Wainwright | $30.00 | $12.17 | 146.51% | 321.35% |
| May 07, 2024 | Graig Suvannavejh | Mizuho Securities | $30.00 | $11.20 | 167.86% | 321.35% |
| Aug 04, 2022 | H.C. Wainwright | $25.00 | $10.22 | 144.62% | 251.12% |
The latest EyePoint Pharmaceuticals stock forecast, released on Nov 11, 2024 by Yi Chen from H.C. Wainwright, set a price target of $22.00, which represents a 89.90% increase from the stock price at the time of the forecast ($11.59), and a 208.99% increase from EYPT last price ($7.12).
EyePoint Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 3 |
| Avg Price Target | - | $22.00 | $27.33 |
| Last Closing Price | $7.12 | $7.12 | $7.12 |
| Upside/Downside | -100.00% | 208.99% | 283.85% |
In the current month, the average price target of EyePoint Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to EyePoint Pharmaceuticals's last price of $7.12. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 28, 2024 | Guggenheim | Buy | Buy | Hold |
| Oct 28, 2024 | Laidlaw | Buy | Buy | Hold |
| Aug 28, 2024 | Jefferies | Buy | Initialise | |
| Aug 13, 2024 | Chardan Capital | Underperform | Underperform | Hold |
| Aug 13, 2024 | J.P. Morgan | Buy | Buy | Hold |
| Jun 27, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 26, 2024 | Laidlaw | Buy | Buy | Hold |
| May 13, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| May 07, 2024 | Chardan Capital | Underperform | Underperform | Hold |
| May 07, 2024 | Mizuho Securities | Buy | Buy | Hold |
| Mar 08, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Nov 11, 2022 | Guggenheim | Buy | Buy | Hold |
EyePoint Pharmaceuticals's last stock rating was published by Guggenheim on Oct 28, 2024. The company gave EYPT a "Buy" rating, the same as its previous rate.
EyePoint Pharmaceuticals Financial Forecast
EyePoint Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | $9.11M | $7.68M | $10.53M | $10.01M | $11.56M | $9.29M | $11.54M | $9.06M | $9.01M | $7.32M | $7.13M | $15.70M | $4.12M | $7.49M | $8.63M | $2.51M | $7.21M | $2.01M | $928.00K | $590.00K |
| Avg Forecast | $1.82M | $1.77M | $6.60M | $6.78M | $10.57M | $10.40M | $10.63M | $9.91M | $8.90M | $7.86M | $79.10M | $7.60M | $10.40M | $10.93M | $10.86M | $9.89M | $9.79M | $9.88M | $8.71M | $7.89M | $18.29M | $13.32M | $3.79M | $7.25M | $7.18M | $3.93M | $6.69M | $3.39M | $806.00K | $590.00K |
| High Forecast | $3.35M | $3.26M | $12.13M | $12.45M | $17.92M | $10.56M | $10.63M | $9.91M | $14.67M | $7.86M | $145.37M | $13.96M | $19.12M | $10.93M | $10.86M | $9.89M | $9.79M | $9.88M | $8.71M | $7.89M | $18.29M | $13.32M | $3.79M | $7.25M | $7.18M | $3.93M | $6.69M | $3.39M | $967.20K | $708.00K |
| Low Forecast | $293.09K | $285.06K | $1.06M | $1.09M | $5.76M | $10.25M | $10.63M | $9.90M | $705.37K | $7.86M | $12.70M | $1.22M | $1.67M | $10.93M | $10.86M | $9.89M | $9.79M | $9.88M | $8.71M | $7.89M | $18.29M | $13.32M | $3.79M | $7.25M | $7.18M | $3.93M | $6.69M | $3.39M | $644.80K | $472.00K |
| # Analysts | 1 | 1 | 1 | 3 | 7 | 3 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 | 17 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.12% | 1.01% | 1.01% | 0.92% | 1.06% | 0.94% | 1.18% | 0.92% | 1.03% | 0.93% | 0.39% | 1.18% | 1.09% | 1.03% | 1.20% | 0.64% | 1.08% | 0.59% | 1.15% | 1.00% |
EyePoint Pharmaceuticals's average Quarter revenue forecast for Sep 23 based on 5 analysts is $7.86M, with a low forecast of $7.86M, and a high forecast of $7.86M. EYPT's average Quarter revenue forecast represents a -13.63% decrease compared to the company's last Quarter revenue of $9.11M (Jun 23).
EyePoint Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 7 | 3 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 | 17 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | $-22.76M | $-20.35M | $-21.77M | $-17.14M | $-18.24M | $-17.53M | $-17.35M | $-14.61M | $-7.95M | $-10.25M | $-12.97M | $-1.29M | $-10.47M | $-10.74M | $-7.97M | $-13.23M | $-9.25M | $-17.56M | $-6.93M | $-4.93M |
| Avg Forecast | $-1.82M | $-1.77M | $-6.60M | $-6.78M | $-10.57M | $-10.40M | $-10.63M | $-17.26M | $-8.90M | $-7.86M | $-79.10M | $-18.46M | $-5.89M | $-10.93M | $-10.86M | $-19.74M | $-9.79M | $-9.88M | $-8.71M | $-9.36M | $-18.29M | $-13.32M | $-3.79M | $-9.67M | $-7.18M | $-3.93M | $-6.69M | $-11.04M | $-5.87M | $-4.93M |
| High Forecast | $-293.09K | $-285.06K | $-1.06M | $-1.09M | $-5.76M | $-10.25M | $-10.63M | $-13.81M | $-705.37K | $-7.86M | $-12.70M | $-14.77M | $-4.71M | $-10.93M | $-10.86M | $-15.80M | $-9.79M | $-9.88M | $-8.71M | $-7.49M | $-18.29M | $-13.32M | $-3.79M | $-7.73M | $-7.18M | $-3.93M | $-6.69M | $-8.83M | $-4.69M | $-3.95M |
| Low Forecast | $-3.35M | $-3.26M | $-12.13M | $-12.45M | $-17.92M | $-10.56M | $-10.63M | $-20.71M | $-14.67M | $-7.86M | $-145.37M | $-22.15M | $-7.06M | $-10.93M | $-10.86M | $-23.69M | $-9.79M | $-9.88M | $-8.71M | $-11.23M | $-18.29M | $-13.32M | $-3.79M | $-11.60M | $-7.18M | $-3.93M | $-6.69M | $-13.24M | $-7.04M | $-5.92M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.29% | 1.10% | 3.70% | 1.57% | 1.68% | 0.89% | 1.77% | 1.48% | 0.91% | 1.10% | 0.71% | 0.10% | 2.76% | 1.11% | 1.11% | 3.36% | 1.38% | 1.59% | 1.18% | 1.00% |
undefined analysts predict EYPT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than EyePoint Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.
EyePoint Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 7 | 3 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 | 17 |
| Net Income | - | - | - | - | - | - | - | - | - | - | $-22.92M | $-21.59M | $-64.15M | $-18.44M | $-19.60M | $-22.54M | $-20.82M | $-16.70M | $-10.01M | $-12.28M | $-15.47M | $-3.80M | $-12.95M | $-13.17M | $-10.41M | $-15.65M | $-11.50M | $-19.24M | $-6.98M | $-5.14M |
| Avg Forecast | $-37.79M | $-36.59M | $-32.12M | $-31.25M | $-27.10M | $-29.72M | $-27.47M | $-18.97M | $-26.48M | $-27.09M | $75.36M | $-20.29M | $-6.13M | $-36.00M | $-27.84M | $-21.70M | $-28.09M | $-21.39M | $-23.94M | $-11.21M | $-3.64M | $-15.96M | $-55.87M | $-11.86M | $-62.52M | $-73.16M | $-63.85M | $-12.09M | $-5.90M | $-5.14M |
| High Forecast | $3.45M | $3.34M | $2.93M | $-25.95M | $-19.53M | $2.71M | $2.51M | $-15.18M | $-17.65M | $2.47M | $157.43M | $-16.23M | $-4.90M | $-36.00M | $-27.84M | $-17.36M | $-28.09M | $-21.39M | $-23.94M | $-8.97M | $-3.64M | $-15.96M | $-55.87M | $-9.49M | $-62.52M | $-73.16M | $-63.85M | $-9.67M | $-4.72M | $-4.11M |
| Low Forecast | $-78.94M | $-76.44M | $-67.11M | $-36.56M | $-33.40M | $-62.09M | $-57.39M | $-22.76M | $-33.54M | $-56.59M | $-6.87M | $-24.35M | $-7.35M | $-36.00M | $-27.84M | $-26.04M | $-28.09M | $-21.39M | $-23.94M | $-13.45M | $-3.64M | $-15.96M | $-55.87M | $-14.23M | $-62.52M | $-73.16M | $-63.85M | $-14.51M | $-7.09M | $-6.17M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | -0.30% | 1.06% | 10.47% | 0.51% | 0.70% | 1.04% | 0.74% | 0.78% | 0.42% | 1.10% | 4.25% | 0.24% | 0.23% | 1.11% | 0.17% | 0.21% | 0.18% | 1.59% | 1.18% | 1.00% |
EyePoint Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. EYPT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
EyePoint Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 7 | 3 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 | 17 |
| SG&A | - | - | - | - | - | - | - | - | - | - | $14.34M | $14.98M | $14.41M | $15.23M | $15.44M | $15.24M | $17.03M | $13.43M | $11.84M | $10.77M | $11.59M | $11.06M | $10.88M | $12.48M | $11.55M | $12.14M | $12.10M | $11.92M | $2.28M | $2.43M |
| Avg Forecast | $2.81M | $2.73M | $10.16M | $10.43M | $16.27M | $16.02M | $16.37M | $15.25M | $13.71M | $12.11M | $121.79M | $11.69M | $2.62M | $16.77M | $16.67M | $15.18M | $15.03M | $15.17M | $13.37M | $12.11M | $28.08M | $20.44M | $5.82M | $11.13M | $11.01M | $6.04M | $10.27M | $5.20M | $1.24M | $905.58K |
| High Forecast | $5.16M | $5.02M | $18.68M | $19.17M | $27.59M | $16.25M | $16.37M | $15.26M | $22.59M | $12.11M | $223.82M | $21.49M | $3.14M | $16.77M | $16.67M | $15.18M | $15.03M | $15.17M | $13.37M | $12.11M | $28.08M | $20.44M | $5.82M | $11.13M | $11.01M | $6.04M | $10.27M | $5.20M | $1.48M | $1.09M |
| Low Forecast | $451.26K | $438.90K | $1.63M | $1.68M | $8.87M | $15.79M | $16.37M | $15.24M | $1.09M | $12.11M | $19.56M | $1.88M | $2.10M | $16.77M | $16.67M | $15.18M | $15.03M | $15.17M | $13.37M | $12.11M | $28.08M | $20.44M | $5.82M | $11.13M | $11.01M | $6.04M | $10.27M | $5.20M | $989.69K | $724.47K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.12% | 1.28% | 5.50% | 0.91% | 0.93% | 1.00% | 1.13% | 0.89% | 0.89% | 0.89% | 0.41% | 0.54% | 1.87% | 1.12% | 1.05% | 2.01% | 1.18% | 2.29% | 1.84% | 2.68% |
EyePoint Pharmaceuticals's average Quarter SG&A projection for Sep 23 is $12.11M, based on 5 Wall Street analysts, with a range of $12.11M to $12.11M. The forecast indicates a -15.59% fall compared to EYPT last annual SG&A of $14.34M (Jun 23).
EyePoint Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 7 | 3 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 | 17 |
| EPS | - | - | - | - | - | - | - | - | - | - | $-0.61 | $-0.58 | $-1.72 | $-0.49 | $-0.53 | $-0.60 | $-0.64 | $-0.58 | $-0.35 | $-0.50 | $-1.07 | $-0.30 | $-1.04 | $-1.14 | $-0.98 | $-1.46 | $-1.08 | $-2.02 | $-1.53 | $-1.50 |
| Avg Forecast | $-0.69 | $-0.67 | $-0.59 | $-0.57 | $-0.50 | $-0.55 | $-0.50 | $-0.40 | $-0.49 | $-0.50 | $1.38 | $-0.68 | $-0.61 | $-0.68 | $-0.52 | $-0.58 | $-0.53 | $-0.40 | $-0.45 | $-0.49 | $-0.07 | $-0.30 | $-1.05 | $-0.95 | $-1.18 | $-1.38 | $-1.20 | $-1.37 | $-0.11 | $-0.15 |
| High Forecast | $0.06 | $0.06 | $0.05 | $-0.48 | $-0.36 | $0.05 | $0.05 | $0.04 | $-0.32 | $0.05 | $2.89 | $0.06 | $0.06 | $-0.68 | $-0.52 | $-0.58 | $-0.53 | $-0.40 | $-0.45 | $-0.49 | $-0.07 | $-0.30 | $-1.05 | $-0.95 | $-1.18 | $-1.38 | $-1.20 | $-1.37 | $-0.09 | $-0.12 |
| Low Forecast | $-1.45 | $-1.40 | $-1.23 | $-0.67 | $-0.61 | $-1.14 | $-1.05 | $-0.84 | $-0.62 | $-1.04 | $-0.13 | $-1.42 | $-1.27 | $-0.68 | $-0.52 | $-0.58 | $-0.53 | $-0.40 | $-0.45 | $-0.49 | $-0.07 | $-0.30 | $-1.05 | $-0.95 | $-1.18 | $-1.38 | $-1.20 | $-1.37 | $-0.13 | $-0.18 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | -0.44% | 0.85% | 2.82% | 0.72% | 1.01% | 1.04% | 1.21% | 1.44% | 0.78% | 1.01% | 15.66% | 1.00% | 0.99% | 1.20% | 0.83% | 1.06% | 0.90% | 1.48% | 13.91% | 10.00% |
According to undefined Wall Street analysts, EyePoint Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to EYPT previous annual EPS of $NaN (undefined).
EyePoint Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VIRX | Viracta Therapeutics | $0.22 | $8.00 | 3536.36% | Buy |
| ALXO | ALX Oncology | $1.79 | $24.50 | 1268.72% | Buy |
| RVPH | Reviva Pharmaceuticals | $1.40 | $10.00 | 614.29% | Buy |
| CABA | Cabaletta Bio | $2.75 | $16.33 | 493.82% | Buy |
| BMEA | Biomea Fusion | $4.64 | $23.33 | 402.80% | Buy |
| XFOR | X4 Pharmaceuticals | $0.74 | $3.67 | 395.95% | Buy |
| IPHA | Innate Pharma | $2.15 | $10.00 | 365.12% | Buy |
| ABOS | Acumen Pharmaceuticals | $1.96 | $7.00 | 257.14% | Buy |
| SLS | SELLAS Life Sciences Group | $0.88 | $2.80 | 218.18% | Buy |
| TERN | Terns Pharmaceuticals | $6.80 | $18.67 | 174.56% | Buy |
| EYPT | EyePoint Pharmaceuticals | $8.02 | $22.00 | 174.31% | Buy |
| MREO | Mereo BioPharma Group | $3.40 | $8.00 | 135.29% | Buy |
| DAWN | Day One Biopharmaceuticals | $12.64 | $24.00 | 89.87% | Buy |
| HOOK | HOOKIPA Pharma | $2.13 | $3.00 | 40.85% | Buy |